Fondaparinux effective and well-tolerated for prevention of VTE in acutely ill patients
Fondaparinux (Arixtra, Organon/Sanofi-Synthelabo) given once daily significantly reduces the risk of venous thromboembolism (VTE) in acutely ill, hospitalized patients, according to data from the Arixtra for ThromboEmbolism prevention in a Medical Indications Study (ARTEMIS).
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
